The vaccines based on the replicon of the venezuelan equine encephalomyelitis virus against viral hemorrhagic fevers

Cover Page

Cite item

Full Text

Abstract

The status of the various recombinant DNA and RNA-derived candidate vaccines, as well as the Venezuelan equine encephalomyelitis virus (VEEV) replicon vaccine system against extremely hazardous viral hemorrhagic fevers, were reviewed. The VEEV-based replication-incompetent vectors offer attractive features in terms of safety, high expression levels of the heterologous viral antigen, tropism to dendritic cells, robust immune responses, protection efficacy, low potential for pre-existing anti-vector immunity and possibility of engineering multivalent vaccines were tested. These features of the VEEV replicon system hold much promise for the development of new generation vaccine candidates against viral hemorrhagic fevers.

About the authors

A. A. Petrov

Federal State Budgetary Establishment «48 Central Scientific Research Institute» of the Ministry of Defence of the Russian Federation

Author for correspondence.
Email: petrov_a_a@rambler.ru

Aleksandr Petrov, MD, PhD

141306, Sergiev Posad – 6

Russian Federation

T. M. Plekhanova

Federal State Budgetary Establishment «48 Central Scientific Research Institute» of the Ministry of Defence of the Russian Federation

Email: fake@neicon.ru
141306, Sergiev Posad – 6 Russian Federation

O. N. Sidorova

Federal State Budgetary Establishment «48 Central Scientific Research Institute» of the Ministry of Defence of the Russian Federation

Email: fake@neicon.ru
141306, Sergiev Posad – 6 Russian Federation

S. V. Borisevich

Federal State Budgetary Establishment «48 Central Scientific Research Institute» of the Ministry of Defence of the Russian Federation

Email: fake@neicon.ru
141306, Sergiev Posad – 6 Russian Federation

A. A. Makhlay

Federal State Budgetary Establishment «48 Central Scientific Research Institute» of the Ministry of Defence of the Russian Federation

Email: fake@neicon.ru
141306, Sergiev Posad – 6 Russian Federation

References

  1. Борисевич И.В., Маркин В.А., Фирсова И.В., Хамитов Р.А., Максимов В.А., Евсеев А.А. Эпидемиология, профилактика, клиника и лечение геморрагических лихорадок. Вопросы вирусологии. 2006; 5: 8–17.
  2. Bausch, D.G. Ebola, Marburg, Lassa, and other hemorrhagic fevers. In: Lashley F.R., Durham J.D., eds. Emerging infectious diseases. New York: Springer Publishing Co.: New York; 2007: 133–57.
  3. Burnett J.C., Henchal E.A., Schmaljohn A.L., Bavari S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. Drug Disc. 2005; 4: 281–97.
  4. Fisher-Hoch S.P., Hutwagner L., Brown B., McCormick J.B. Effective vaccine for Lassa fever. J. Virol. 2000; 74: 6777–83.
  5. Lassa fever imported case United Kingdom. Wkly Epidemiol. Rec. 2000; 75 (11): 85.
  6. Outbreak of Marburg hemorrhagic fever – Angola. October 1, 2004– March 29, 2005. MMWR Morb. Mortal. Wkly. Rep. 2005; 54 (12): 308–9.
  7. Maiztegui J.I., McKee K.T.Jr., Oto B.J.G., Harrison L.H., Gibbs P.H., Feuillade M.R. et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J. Infect. Dis. 1998; 177 (2): 277–83.
  8. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R. et al. Development of a new vaccine for the prevention of Lassa fever. PloS. Med. 2005; 2 (6): 537–45.
  9. Grant-Klein R.J., Altamura L.A., Schmaljohn C.S. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. Virus Res. 2001; 162: 148–61.
  10. Bausch D.G., Geisbert T.W. Development of vaccines for Marburg hemorrhagic fever. Expert Rev. Vaccines. 2007; 6 (1): 57–74.
  11. Geisbert T.W., Bailey M., Hensley L., Asiedu C., Geisbert J., Stanley D., et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 2011; 85 (9): 4222–33.
  12. Hevey M., Negley D., VanderZanden L. Tammariello R.F., Geisbert J., Schmaljohn C. et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine. 2001; 20 (3–4): 586–93.
  13. Riemenschneider J., Garrison A., Geisbert J., Jahrling P., Hevey M., Negley D. et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21 (25–26): 4071–80.
  14. Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H. et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 2008; 15 (3): 460–7.
  15. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A. et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin. Vaccine Immunol. 2006; 13 (11): 1267–77.
  16. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 2005; 11 (7): 786–90.
  17. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A. et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 2005: 79 (10): 6516–22.
  18. DoD selects Paragon Bioservices for Filovirus vaccine contract – See more at: http://www.centerwatch.com/news-online/article/2775/ (Wednesday, January 18, 2012 12:15 PM).
  19. Davis N.L., West A., Reap E., MacDonald G., Collier M., Dryga S. et al. Alphavirus Replicon Particles As Candidate HIV vaccines. IUBMB Life. 2002; 53 (4–5): 209–11.
  20. Zimmer G. RNA Replicons – a new approach for influenza virus immunoprophylaxis. Viruses. 2010; 2: 413–34.
  21. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001; 75 (23): 11677–85.
  22. Vander Veen R.L., Harris D.L.H., Kamrud K.I. Alphavirus replicon vaccines. Animal Health Res. Rev. 2012; 13 (1): 1–9.
  23. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 2000; 74 (2): 914–22.
  24. Lundstrom K. Alphavirus vectors in vaccine development. J. Vaccines Vaccination. 2012; 3 (3): 139–47.
  25. Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L. et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine. 2006; 24 (47-48): 6886–92.
  26. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998; 251 (1): 28–37.
  27. Friedrich B.M., Trefry J.C., Biggins J.E. Potential vaccines and post-exposure treatments for filovirus infections. Viruses. 2012; 4: 1619–50.
  28. Garbutt M.R., Liebscher R., Wahl-Jensen V., Jones S., Möller P., Wagner R. et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 2004; 78 (10): 5458–65.
  29. Bredenbeek P.J., Molenkamp R., Spaan W.J., Deubel V., Marianneau P., Salvato M.S. et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology. 2006; 345 (2): 299–304.
  30. Jiang X., Dalebout T.J., Bredenbeek P.J., Carrion R.Jr., Brasky K., Patterson J. et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011; 29 (6): 1248–57.
  31. Branco L.M., Grove J.N., Geske F.J. Boisen M.L., Muncy I.J., Magliato S.A. et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 2010; 7: 279–83.
  32. Rodriguez-Carreno M.P., Nelson M.S., Botten J., Smith-Nixon K., Buchmeier M.J., Whitton J.L. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology. 2005; 335 (1): 87–98.
  33. Seregin A.V., Yun N.E., Poussard A.L. Peng B.H., Smith J.K., Smith J.N. et al. TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. Vaccine. 2010; 28 (30): 4713–8.
  34. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003; 424 (6949): 681–4.
  35. Sullivan N.J., Sanchez A. Development off preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408: (6812): 605–9.
  36. Swenson D.L., Warfield K.L., Negley D.L. Virus-like particles exhibit potential as a panfilovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005; 23 (23): 3033–42.
  37. Warfield K.L., Aman M.J. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis. 2011; 204: 1053–9.
  38. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Javad A.M., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007; 196 (2): 430–7.
  39. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 2002; 8 (5): 503–7.
  40. Pushko P., Bray M., Ludwig G.V., Parker M., Schmaljohn A., Sanchez A. et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000; 19 (1): 142–53.
  41. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F. et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006; 346 (2): 394–401.
  42. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., Strong J.E., Feldman H. et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One. 2009; 4 (4): 5308–10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Petrov A.A., Plekhanova T.M., Sidorova O.N., Borisevich S.V., Makhlay A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies